press release

May 5, 2017

- Initial Data Support Potential for ALN CC5 to Reduce Dose and Frequency of Eculizumab Initial Results Also Support Potential for ALN CC5 to Improve Disease Control in Eculizumab Inadequate Responders Company to Host Conference Call Today, June 11, at 8:30 am ET to Discuss Results CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...

press release

May 5, 2017

- Advances Pipeline of Ten Clinical Stage Programs, with Ten Additional Clinical Data Readouts Anticipated This Year Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial in Late 2016 with Data Readout in Mid 2018 On Track to Start Fitusiran Phase 3 Program in Mid 2016; Plans to Report Updated Hemophilia Patient Data in July Provides Update ...

press release

May 5, 2017

- Expects to Report Initial Clinical Activity Data in Late 2016 Receives Both U.S. and EU Orphan Drug Designations CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN GO1, a subcutaneously administered investigational RNAi therapeutic for ...

press release

May 5, 2017

- Advanced Pipeline of Eight Clinical Stage Programs in 2015, with Ten or More Major Clinical Data Readouts, Start of Fitusiran Phase 3 Trials, and Three New IND Filings Planned in 2016 Completed Enrollment in Patisiran Phase 3 APOLLO Trial, Positioning the Company for First Filing for Regulatory Approval in 2017 Maintained Strong Balance Sheet with $1.28 Billion ...

press release

May 5, 2017

- Achieves Dose Dependent Lowering of Antithrombin of Up to 88 Percent, Clinically Meaningful Increases in Thrombin Generation, and Reductions of 85 Percent in Median Estimated Annualized Bleeding Rates Fitusiran Shown to be Generally Well Tolerated to Date, with no Significant Changes in Levels of D Dimer, a Biomarker of Excessive Clot Formation Company Remains on Track ...

press release

May 5, 2017

- Company Plans to Initiate Phase 1 Study in Early 2016 and Expects to Report Initial Clinical Data in Late 2016 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency ...

press release

May 5, 2017

- Ten Major Clinical Data Readouts Expected in 2016 By End 2017, Expect Five or More Ongoing Phase 3 Trials and First Phase 3 Readout CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today at a presentation in New York City will discuss pipeline progress across its three strategic ...

press release

May 5, 2017

- Up to 53 percent Maximal and 47 percent Least Squares Mean Reduction in LDL C Achieved at 6 Months after Single, Low Volume, Subcutaneous Injection ALN PCSsc Also Achieves Major Reductions in Other Atherogenic Lipids, Including Lowering of Lp(a) and Total Cholesterol of up to 77 percent and 55 percent, Respectively Companies On Track to Initiate ...

press release

May 5, 2017

.bwalignc {text align: center} In Addition, Investigational ALN CC5 Achieves Low Levels of Residual Serum C5 at or Below Levels of Free C5 Estimated from Reports with an Approved Anti C5 Monoclonal Antibody ALN CC5 Shown to be Generally Well Tolerated with No Clinically Significant, Drug Related Adverse Events to Date Alnylam Remains on Track to Initiate Dosing ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day live on the Investors section of the company's website, www.alnylam.com the morning of December 10, 2015. Alnylam management and leading physicians will discuss development candidates from the ...